...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference

Summer 2019, that's a lot of wiggle room.  Right now, based on DM's April forecast for hitting 250 events, followed by a 2-3 month adjudication period....that puts the H1 June 30th target within the realm of possibility.  If the trial stopped dosing at the end of April, 2-3 months would mean June or July to Top-Line.

Of course summer 2019 doesn't end until Sept 21 (or within a day of that date).....

And of course its something that is "expected" which means it is not a material fact and hence should not be relied upon....

Share
New Message
Please login to post a reply